Mind Cure makes addition to its team
Moonbeam Functional Mushrooms in final testing stage
VANCOUVER, Sept. 24, 2020 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce the addition Alain Roy to the company. Alain Roy is a product development expert with over 30 years of experience creating and manufacturing high-quality health supplements and nutritional products for leading brands such as Vega, greens+ and Bio-K+.
This addition highlights Mind Cure’s focus on building its team to evaluate, identify and deliver safe, high-quality and effective nootropic and functional mushroom products to the market, beginning with the launch of Moonbeam Mushrooms. Mind Cure is also pleased to announce that its Moonbeam Mushrooms products are in the final stages of testing and manufacturing before launching to the Canadian and US markets.
Alain Roy is a product development specialist with over 30 years of experience creating and manufacturing high-quality health supplements in Canada, working with leading brands such as greens+, Bio-K+ and Vega, among others. He has extensive experience with Health Canada and developing compliant natural health products for the Canadian marketplace.
“I have the luxury of picking who I work with very carefully. I now choose to work only with those brands I strongly align with, and in particular brands that are dedicated to doing things right in terms of quality manufacturing,” said Alain Roy. “Mind Cure and its team are committed to developing only the highest quality of functional and nootropic products.”
Philip Tapley stated, “Alain Roy brings instant credibility to Mind Cure. He is an award-winning product developer who has helped to create some of the most successful health supplements in the world. As we research and discover nootropic products for the Mind Cure consumer, Alain’s expertise with manufacturing, growth and compliance will enable us to help more people more quickly.”
Additionally, Mind Cure is announcing today that they are rapidly approaching the launch of Moonbeam Mushroom products in the USA. Currently, the products are in the final phase of manufacturing and testing, and the company anticipates an early-October launch for direct sales to U.S. consumers.
Mind Cure believes that the mental health space is ready for transformation, and that innovation and investment will lead to a major disruption in how mental health is treated. Mind Cure intends to further its investigation into new product candidates and treatments which are effective in treating mental health. These new product candidates range from nootropics, psychoactive products, and psychedelic substances.
About Mind Cure Health Inc.
Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure.
On Behalf of the Board of Directors
Philip Tapley, Chairman, President, and CEO
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward- looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mind Cure’s focus on building its team to evaluate, identify and deliver nootropic and functional mushroom products; the intention to launch products in the Canadian and US markets and the timing thereof; Mind Cure’s strategy; the anticipated benefit of Dr. Ocana and Alain Roy; anticipated timing for direct sales to US consumers; the belief that the mental health space is ready for transformation and that innovation and investment will lead to a major disruption in how mental health is treated; the intention of further investigation into new product candidates and treatments; the range of new products of Mind Cure and Mind Cure being able to identify, develop and commercialize products.
Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; the addition of Dr. Ocana and Alain Roy will help Mind Cure to evaluate, identify and deliver safe, high-quality and effective nootropic and functional mushroom products; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure’s industry and Mind Cure’s business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure’s investments, results of operations, financial condition and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; the addition of Dr. Ocana and Alain Roy may not help Mind Cure to evaluate, identify and deliver safe, high-quality and effective nootropic and functional mushroom products; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Mind Cure Health Inc.
For further information: Investor Relations: email@example.com, 1-888-593-8995